Long-acting Copaxone to launch early next year in Europe, Teva says

Teva ($TEVA) has already surprised analysts with the success it's had converting patients from multiple sclerosis star Copaxone to a new, long-acting version. And now, the company is preparing to take the med to Europe. On Thursday, Teva announced it had received a positive outcome in the decentralized procedure for the drug and that "granting of national authorizations will happen in the near future." The Israeli drugmaker plans to make the med available on the continent as early as the first quarter of 2015, with launches in Germany, Netherlands and Denmark, it said. It expects others to follow throughout the year. Release | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.